ArticleFrontiers in cardiovascular medicine2025
Systemic light chain cardiac amyloidosis with atrioventricular block.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Systemic light-chain (AL) amyloidosis is a rare plasma cell disorder with an annual incidence of approximately 8-12 cases per million population in regions with advanced diagnostic capabilities. Cardiac involvement occurs in 60%-75% of patients, and without treatment, the median survival is only six months. Atrioventricular (AV) conduction block affects approximately 3%-5% of AL patients. Although current therapies can induce deep hematologic remission and often significantly reverse myocardial structural and functional abnormalities, residual amyloid deposits may still trigger delayed, life-threatening conduction system events. Illustrative case: We describe a representative 50-year-old male patient with AL cardiac amyloidosis who achieved deep hematologic remission after standard anti-plasma cell therapy and autologous stem cell transplantation. Echocardiography demonstrated marked improvement in both myocardial structure and systolic/diastolic function. Nevertheless, he presented with syncope. An implantable cardiac monitor (ICM) captured a 7-second episode of asystole. A permanent pacemaker was subsequently implanted, resulting in complete resolution of syncope. Notably, atrial arrhythmias markedly decreased thereafter, and no episodes of paroxysmal atrial fibrillation have been documented on serial ambulatory electrocardiography or remote ICM monitoring during follow-up. Conclusions: This case highlights a crucial principle in the management of AL amyloidosis: improvement in hematologic status and cardiac structure/function does not equate to electrophysiologic stability. In high-risk patients, vigilance for occult conduction disease must persist even after clinical recovery. The ICM serves as a pivotal "bridge" tool to detect intermittent, life-threatening bradyarrhythmias and guide timely, precise device-based intervention. These findings underscore the need for individualized, long-term cardiac electrophysiological monitoring strategies in patients with AL-CA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.